Calcium

Calcium operates through two distinct mechanistic domains: structural (the mineral phase of bone and teeth, hydroxyapatite [Ca10(PO4)6(OH)2]) and signaling (the universal second messenger in virtually every eukaryotic cell). The two are separated by a 10,000-fold concentration gradient, sophisticated hormonal regulation, and a dense network of channels, pumps, buffers, and effector proteins. Understanding calcium requires tracing flux across membranes and organelles and mapping the downstream effectors that translate calcium transients into cellular actions.

Calcium homeostasis. Extracellular ionized calcium is maintained at 1.10-1.30 mmol/L by an integrated hormonal system. Parathyroid chief cells express the calcium-sensing receptor (CaSR), a class C G-protein-coupled receptor that activates Gq and Gi when bound by Ca2+, inhibiting PTH secretion. Falling ionized calcium reduces CaSR activation, releasing the brake on PTH secretion. PTH acts on bone (stimulating osteoblast-mediated RANKL expression driving osteoclast activation and resorption with release of calcium and phosphate), kidney (increasing distal tubular calcium reabsorption via TRPV5 and calbindin-D28k, decreasing proximal phosphate reabsorption, and activating 1α-hydroxylase CYP27B1 to produce calcitriol), and has limited direct intestinal action. Calcitriol acts on the intestine (upregulating TRPV6, calbindin-D9k, PMCA1b to improve active calcium absorption), bone (permissive for PTH effects and osteoblast mineralization), and kidney. The CaSR is itself a therapeutic target; cinacalcet (a calcimimetic) activates CaSR allosterically to suppress PTH in secondary hyperparathyroidism and in parathyroid carcinoma.

Calcitonin, from thyroid C cells, rises with hypercalcemia and modestly inhibits osteoclast bone resorption. Its physiologic role in adult calcium homeostasis is minor; calcitonin deficiency (post-thyroidectomy) does not cause clinical abnormality, but pharmacologic calcitonin has been used (historically) for Paget disease and hypercalcemia of malignancy.

FGF23, secreted by osteocytes in response to elevated phosphate and calcitriol, suppresses renal 1α-hydroxylase (reducing calcitriol), reduces PTH, and reduces phosphate reabsorption in proximal tubule — integrating phosphate and calcium/vitamin D homeostasis. Hereditary hypophosphatemic rickets (XLH, ADHR, ARHR) involves FGF23 dysregulation.

Intestinal absorption. Transcellular: at low-to-moderate intakes (physiologic range), TRPV6 channel on the apical membrane allows Ca2+ entry down its electrochemical gradient into enterocytes; calbindin-D9k binds Ca2+ and shuttles it to the basolateral membrane (maintaining low free cytosolic Ca2+ to prevent apoptotic signaling); PMCA1b actively extrudes Ca2+ across the basolateral membrane into interstitial fluid. All three proteins (TRPV6, CaBD-9k, PMCA1b) are transcriptionally upregulated by calcitriol via VDR. Paracellular: at higher intakes, calcium flows through tight junctions (claudin-2 and claudin-12 are the relevant calcium-permeable claudins) driven by luminal concentration; this pathway is less vitamin D-dependent. Magnesium competes with calcium at shared absorption sites; very high dietary magnesium can modestly reduce calcium absorption. Phytates, oxalates, and excessive dietary fiber reduce calcium bioavailability by forming insoluble complexes in the intestinal lumen.

Renal handling. Filtered calcium is reabsorbed 65% in the proximal tubule (paracellular, linked to sodium reabsorption), 20-25% in the thick ascending limb of Henle (paracellular via claudin-16/19, driven by the lumen-positive voltage gradient), 5-10% in the distal convoluted tubule (transcellular via TRPV5, calbindin-D28k, PMCA1b, and NCX1 — strongly PTH-regulated and vitamin D-regulated), and <1% is excreted. The distal tubule is the hormonal regulation point. Thiazide diuretics reduce urinary calcium by improving distal reabsorption — used therapeutically in hypercalciuric stone formers. Loop diuretics increase urinary calcium loss and can cause hypercalciuria contributing to osteoporosis with long-term use.

Bone mineralization. Osteoblasts secrete collagen type I and non-collagenous proteins (osteocalcin, osteonectin, osteopontin, bone sialoprotein) forming osteoid, a calcifiable matrix. Mineralization occurs when osteoblast-derived matrix vesicles — small membrane-bound structures — accumulate calcium and phosphate through alkaline phosphatase (which liberates phosphate from pyrophosphate and organic phosphate compounds, also removing the endogenous mineralization inhibitor pyrophosphate) and annexins (calcium channels). Hydroxyapatite crystals nucleate within matrix vesicles and then propagate into the surrounding collagen fibrils, creating structural mineralized bone. Carboxylated osteocalcin binds hydroxyapatite and regulates crystal size and orientation; undercarboxylated osteocalcin (as occurs in vitamin K deficiency) impairs this. Matrix Gla protein (MGP) is secreted by vascular smooth muscle and chondrocytes; carboxylated MGP binds calcium and inhibits inappropriate vascular and cartilage calcification. Vitamin K2 deficiency produces undercarboxylated osteocalcin and MGP, creating the "calcium paradox" in which supplemental calcium may be directed toward vascular calcification rather than bone.

Bone resorption. Osteoclasts (multinucleated cells differentiated from monocyte/macrophage lineage under RANKL/RANK signaling) attach to bone surface via αvβ3 integrin, form a sealed resorption lacuna (Howship lacuna), secrete H+ via V-ATPase and chloride via ClC-7 creating pH ~4.5 that dissolves hydroxyapatite, and secrete cathepsin K (primary collagenase in bone) that degrades the organic matrix. Osteoclast differentiation requires RANKL (receptor activator of NF-κB ligand, secreted by osteoblasts and osteocytes) binding RANK on osteoclast precursors; osteoprotegerin (OPG) is a decoy receptor for RANKL secreted by osteoblasts, inhibiting osteoclastogenesis. The RANKL/OPG ratio governs bone remodeling balance. Denosumab is a monoclonal antibody against RANKL — the most potent anti-resorptive drug currently available. Bisphosphonates (alendronate, risedronate, zoledronate) bind to hydroxyapatite at resorption sites and inhibit osteoclast farnesyl pyrophosphate synthase, triggering osteoclast apoptosis. Estrogen acts on both osteoblasts (increases OPG) and osteoclasts (inducing apoptosis), explaining postmenopausal bone loss.

Intracellular calcium signaling. Cytosolic free calcium is maintained at 50-100 nmol/L (approximately 10,000-fold lower than extracellular). Calcium entry pathways include voltage-gated calcium channels (Cav1.x / L-type, Cav2.x / P/Q/N/R-type, Cav3.x / T-type; L-type calcium channels in cardiac muscle are the dihydropyridine/amlodipine target), receptor-operated channels (NMDA glutamate receptors in neurons are calcium-permeable), store-operated channels (Orai1-STIM1 CRAC channels activated by ER calcium depletion), TRP channels (TRPC, TRPV6 for intestinal absorption as above), and plasma membrane Na+/Ca2+ exchanger (NCX) reverse mode. ER/SR calcium release is mediated by IP3 receptors (IP3R1-3, activated by inositol trisphosphate downstream of Gq/PLC signaling) and ryanodine receptors (RyR1 skeletal muscle, RyR2 cardiac muscle, RyR3 brain, activated by calcium-induced calcium release or direct receptor interaction with dihydropyridine receptors in skeletal muscle). Calcium extrusion is by SERCA (ER/SR calcium ATPase, refilling stores) and PMCA (plasma membrane calcium ATPase, extruding to extracellular). Mitochondrial calcium uptake occurs through the mitochondrial calcium uniporter (MCU) in the inner membrane, driven by the mitochondrial membrane potential; mitochondrial calcium regulates TCA cycle dehydrogenases and at high levels triggers mitochondrial permeability transition pore and apoptosis.

Calcium-dependent effectors. Calmodulin is the most versatile calcium-binding protein, a 17 kDa calcium sensor with four EF-hand calcium binding sites; when activated by four Ca2+, calmodulin activates dozens of downstream kinases (CaMKI, II, IV, CaM kinase kinase), phosphatases (calcineurin PP2B, the cyclosporine/tacrolimus target), phosphodiesterases, and other enzymes, shaping long-term potentiation in neurons, immune signaling, and smooth muscle contraction. Troponin C is the striated muscle calcium sensor; calcium binding exposes myosin-binding sites on actin, enabling the cross-bridge cycle and muscle contraction. Synaptotagmin is the calcium sensor for synaptic vesicle fusion; calcium binding triggers SNARE-mediated membrane fusion and neurotransmitter release. Calcineurin dephosphorylates NFAT transcription factors enabling nuclear translocation — central to T cell activation and cyclosporine/tacrolimus mechanism. Calpain is calcium-activated protease.

Cardiac excitation-contraction coupling. Cardiac action potential opens L-type voltage-gated calcium channels (Cav1.2, DHPR) allowing a small calcium influx during plateau phase; this calcium triggers calcium-induced calcium release from sarcoplasmic reticulum via RyR2; the resulting calcium transient binds troponin C, shifts tropomyosin, and enables actin-myosin cross-bridging for systole. SERCA2a re-sequesters calcium into SR and NCX extrudes calcium across plasma membrane for diastole. This is why calcium channel blockers (amlodipine, diltiazem, verapamil) reduce cardiac contractility and vascular smooth muscle tone.

Platelets and coagulation. Calcium is factor IV in the classical coagulation cascade — required as cofactor for virtually every step. In vitro, calcium chelators (citrate, EDTA) are used for anticoagulation in blood collection tubes and dialysis. In vivo, platelet activation and the tenase/prothrombinase complexes all require calcium. Carboxylated clotting factors II, VII, IX, X, and proteins C, S, Z require vitamin K2 for γ-carboxylation of glutamate residues, creating Gla residues that bind calcium and anchor the factors to phospholipid membranes at sites of clot formation.

Calcium is the most abundant mineral in the human body — roughly 1,000 to 1,500 grams in a 70 kg adult, with 99% sequestered in the skeleton and teeth as crystalline hydroxyapatite [Ca10(PO4)6(OH)2], and the remaining 1% distributed across extracellular fluid, intracellular cytoplasm, mitochondria, and the endoplasmic/sarcoplasmic reticulum. That small 1% operates one of biology's most exquisitely regulated signaling systems: extracellular calcium is maintained at 1.10-1.35 mmol/L (total) and 1.10-1.30 mmol/L (ionized) with homeostatic precision rivaling blood glucose and pH, while intracellular cytosolic free calcium rests at roughly 50-100 nmol/L — a 10,000-fold concentration gradient across the plasma membrane that allows transient calcium influxes to function as universal signaling events. Muscle contraction, neurotransmitter release, hormone secretion, fertilization, enzyme activation, gene transcription, apoptosis — calcium signaling sits at the heart of all of them. Humphry Davy isolated elemental calcium metal in 1808 by electrolysis of lime (CaO); the dietary essentiality of calcium for bone formation was recognized in the 19th century; and the modern era of calcium biology dates from Sydney Ringer's 1883 discovery that frog hearts required calcium in perfusate to contract, opening a century of work culminating in the Nobel Prize-winning calcium channel and calcium-sensing receptor characterizations.

The adult RDA for calcium is 1,000 mg/day for most adults and 1,200 mg/day for women over 50 and all adults over 70, with tolerable upper intake level set at 2,500 mg/day for adults 19-50 and 2,000 mg/day for those over 50. Children require 700-1,300 mg/day depending on age. Pregnancy and lactation maintain the adult RDA because calcium economy shifts (increased intestinal absorption offsets fetal and breast-milk demand). The average US diet provides 900-1,100 mg/day from dairy (major contributor), tofu made with calcium sulfate, leafy greens (with varying bioavailability — spinach has high oxalate and poor absorption while kale, bok choy, and collards are well-absorbed), fortified foods (plant milks, juices, cereals), fish with edible bones (sardines, canned salmon), almonds, and fortified breakfast cereals. Calcium supplementation is one of the most common supplement uses worldwide, particularly in postmenopausal women for osteoporosis prevention — but its evidence base is substantially more nuanced than the marketing suggests.

Calcium absorption occurs primarily in the small intestine via two mechanisms. Active transcellular uptake in the duodenum and proximal jejunum is vitamin D-dependent: calcitriol (1,25-dihydroxyvitamin D3) upregulates TRPV6 (the apical calcium channel), calbindin-D9k (cytosolic calcium buffer/shuttle), and PMCA1b (basolateral calcium ATPase extrusion pump), enabling calcium uptake against its electrochemical gradient. This system saturates at intake approaching 200-300 mg per meal and is rate-limited by vitamin D adequacy and calbindin expression. Passive paracellular absorption across the jejunum and ileum handles the majority of calcium absorbed at higher intakes, operating by diffusion through tight junctions driven by luminal calcium concentration. The net absorption fraction is 25-35% from dairy in adults, up to 50-60% in infants and growing children, 10-15% from vegetables with significant oxalate content, 45-60% from bok choy and kale, and 20-45% from supplement forms depending on gastric acid and meal context. Calcium absorption declines with age (reduced vitamin D and mucosal responsiveness) and is impaired by achlorhydria, proton pump inhibitor therapy, and severe gastric resection.

Once absorbed, calcium circulates in plasma in three pools: ionized (free Ca2+, ~50%, the biologically active species), protein-bound (primarily to albumin, ~40%, with smaller amounts bound to globulins), and complexed with small molecules (citrate, phosphate, sulfate, ~10%). Ionized calcium is the regulated species; total calcium measurements must be interpreted in the context of albumin level (correction formula: corrected Ca = measured Ca + 0.02 × [4.0 - albumin g/dL] in SI units) or ionized calcium can be measured directly. Serum calcium is maintained within a narrow range by an integrated hormonal system: parathyroid hormone (PTH, secreted by chief cells when calcium-sensing receptor [CaSR] detects falling ionized calcium) increases bone resorption, enhances renal calcium reabsorption, and stimulates renal 1α-hydroxylase (CYP27B1) to produce calcitriol; calcitriol increases intestinal calcium absorption and potentiates PTH effects on bone; calcitonin (from thyroid C cells) modestly inhibits osteoclast activity in response to high calcium; and FGF23 (fibroblast growth factor 23, from osteocytes) regulates phosphate and suppresses calcitriol.

The bone biology story is extensively integrated with vitamin D3 and vitamin K2. Osteoblasts secrete osteoid — a collagen-rich matrix that mineralizes through hydroxyapatite deposition. Osteoblasts also produce osteocalcin and matrix Gla protein (MGP), both vitamin K-dependent γ-carboxylated proteins that regulate mineralization; osteocalcin promotes hydroxyapatite formation in bone matrix, while MGP (expressed in arterial walls) inhibits vascular calcification. This dual system — vitamin K driving calcium deposition where it should go (bone) and inhibiting deposition where it should not go (arteries) — is why the current biohacker consensus around "calcium paradox" argues for K2-MK7 co-supplementation with calcium to direct calcium away from vascular plaque. Osteoclasts resorb bone through H+ secretion creating an acidic resorption lacuna that dissolves hydroxyapatite, combined with collagenase release to degrade the organic matrix. The balance between osteoblast-mediated formation and osteoclast-mediated resorption is regulated by the RANK/RANKL/OPG axis (osteoblasts express RANKL, osteoclasts express RANK, and osteoprotegerin OPG is a decoy receptor inhibiting RANKL); estrogen loss at menopause shifts this balance toward resorption, and the resulting bone loss is the foundation of postmenopausal osteoporosis — and the rationale for calcium supplementation in this population.

The Women's Health Initiative (WHI) calcium + vitamin D trial (Jackson 2006 NEJM) is the largest randomized controlled trial of calcium supplementation in postmenopausal women — 36,282 women randomized to calcium carbonate 1,000 mg/day + vitamin D3 400 IU/day vs. placebo, 7 years of follow-up. The trial showed a small 1% improvement in hip bone density and a 12% reduction in hip fracture in the active arm, but this was not statistically significant in the primary intention-to-treat analysis. In a per-protocol analysis among adherent women (>80% compliance), hip fracture was reduced 29%, reaching significance. A more concerning signal emerged: a 17% increased incidence of kidney stones in the supplementation arm (confirmed signal). Subsequent Bolland meta-analyses (2008, 2010, 2011, culminating in BMJ 2011) reported that calcium supplementation (with or without vitamin D) was associated with approximately 25-30% increased myocardial infarction risk in older adults, a finding that generated substantial controversy. Re-analyses, particularly of WHI by Prentice 2013, disputed the cardiovascular signal, and more recent large-scale data (EPIC-Heidelberg, UK Biobank analyses) have produced mixed findings. The current pragmatic consensus: prefer dietary calcium whenever possible, keep supplementation to 500-600 mg/day when needed (taken in divided doses), combine with vitamin D and K2, and focus supplementation on women with documented low dietary intake or established osteoporosis rather than blanket use in everyone over 50.

Colorectal cancer is another positive but modest signal. The Calcium Polyp Prevention Study (Baron 1999 NEJM, PMID 9887161) randomized 930 patients with prior colorectal adenoma to calcium carbonate 1,200 mg/day vs. placebo for 4 years; the active arm showed a 19% reduction in recurrent adenoma (RR 0.81, 95% CI 0.67-0.99). Subsequent European calcium supplementation trials have shown similar modest benefit, though the effect disappears when supplementation stops. Dietary calcium intake inversely correlates with colorectal cancer risk in large cohort studies (WCRF 2018 continuous update). Dosing for prevention is typically 1,200 mg/day from food and supplements combined.

Blood pressure. The DASH diet trial (Appel 1997 NEJM, PMID 9099655) provided evidence that dietary patterns high in calcium (from low-fat dairy), potassium, and magnesium, combined with reduced sodium, reduce systolic blood pressure by 5-11 mmHg. Isolated calcium supplementation has shown smaller, less consistent effects on blood pressure (1-2 mmHg reductions in meta-analyses); the DASH pattern is more effective than calcium pills.

Preeclampsia prevention. Calcium supplementation 1-2 g/day in pregnancy has been studied for preeclampsia prevention. Meta-analyses (Hofmeyr Cochrane 2018, PMID 30277579) indicate a 55% reduction in preeclampsia in low-calcium-intake populations (pooled benefit from 13 trials), leading to WHO recommendation for calcium supplementation during pregnancy in populations with low dietary calcium. In well-nourished populations, benefit is marginal.

Kidney stones paradox. High dietary calcium reduces stone risk (via intestinal oxalate binding preventing oxalate absorption); high supplemental calcium, particularly when taken between meals, increases stone risk (elevated urinary calcium without intestinal oxalate binding). Curhan 1997 (NEJM) established this dietary/supplement distinction. Recommendations for stone formers: calcium from food with meals is protective, supplements taken between meals are risky. Calcium citrate is generally preferred over calcium carbonate in stone formers because citrate itself is an inhibitor of stone formation.

BodyHackGuide's take: calcium is essential and highly regulated, but the modern public-health narrative of "calcium supplement = bone health" overreaches the evidence. Dietary calcium from dairy, fortified plant milks, tofu, leafy greens, sardines, almonds, and calcium-fortified foods should be the primary strategy; a Mediterranean-style diet usually delivers 800-1,200 mg/day without effort. Supplementation at 500-600 mg/day (in divided doses, with meals, preferably calcium citrate for PPI users and stone formers, carbonate for others) is reasonable for documented low intake or established osteoporosis. Combine with vitamin D3 2,000-4,000 IU/day, vitamin K2 MK-7 100-180 μg/day, magnesium 300-400 mg/day, and adequate protein intake. Weight-bearing exercise and resistance training do more for bone than calcium supplementation alone. Avoid high-dose (>1,500 mg/day supplemental) calcium given cardiovascular signal concerns, stone risk, and the declining evidence for incremental bone benefit.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Calcium Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Related Articles

Data Completeness

Research Credibility